DIO 901

Drug Profile

DIO 901

Alternative Names: DIO-901; Very Low Dose Glucagon; VLDG

Latest Information Update: 30 Dec 2009

Price : $50

At a glance

  • Originator DiObex
  • Class Antihyperglycaemics; Hormones; Peptides
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypoglycaemia

Most Recent Events

  • 05 Feb 2009 Clinical development is ongoing in USA
  • 18 Mar 2008 DiObex and Camurus sign a license agreement to develop DIO 901 in an ER formulation using FluidCrystal® delivery technology for Hypoglycaemia
  • 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the Metabolic disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top